Femasys doubles enrolling sites to 12 in FemBloc FINALE pivotal trial for permanent birth control
Bitget2026/10/14 13:00- Femasys doubled actively enrolling U.S. sites to 12 for its FemBloc FINALE pivotal trial in non-surgical permanent birth control.
- No trial results were presented; the expanded enrollment is intended to support completion of the U.S. study and an FDA filing.
- FemBloc is positioned as an office-based alternative to surgical sterilization, aiming to avoid anesthesia, incisions, and recovery time.
- Europe has already cleared FemBloc, enabling post-market real-world evidence collection to complement the U.S. pivotal dataset.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
